Click here to search courses using NAPNAP's previous Course Catalog layout.

Title
Category
Credits
Event date
Cost
  • Primary Care
  • FREE for Members
  • Immunization
  • Pharmacology CE
  • 1.25 Contact hours
$12.50
1.25 NAPNAP Contact Hour of which 1.25 contain pharmacology content. This continuing education activity is free for NAPNAP Members. For non-members, this continuing education activity rate is $12.50. This course is an archived presentation from NAPNAP's 2023 National Conference and is offered free with a coupon for conference attendees until 12/31/23. While presenting the latest CDC immunization information, Dr. Koslap-Petraco will share real life experiences and case studies to engage and challenge you to educate and vaccinate your patient families, especially those who question the need for vaccines.
  • Primary Care
  • FREE for Members
  • Infectious Disease
  • Pharmacology CE
  • 1.00 Contact hours
$0.00
1.0 NAPNAP Contact Hour, of which 025 contains pharmacology. This continuing education activity is free to National Association of Pediatric Nurse Practitioners (NAPNAP) members and non-members. This course is an archived presentation from NAPNAP's 2023 National Conference. Lyme disease is the most common vector-borne disease in the United States, with approximately 476,000 people diagnosed and treated each year. Pediatric-focused APRNs in both high- and low-incidence areas may encounter Lyme disease, particularly with endemic areas expanding and increased patient travel. A 2022 survey of more than 600 nurse practitioners and other health care providers revealed that the respondents do not have strong confidence in their Lyme disease knowledge, and provider knowledge gaps exist regarding the appropriate diagnosis and treatment of Lyme disease. This session will review key findings of this survey and address common misconceptions in the diagnosis and treatment of Lyme disease. NAPNAP was awarded funding for to support this education via CDC’s Mobilizing Pediatric Provider Networks: An Education and Training Initiative to Prevent and Control Infectious Disease Threats federal project.
  • FREE for Members
  • Infectious Disease
  • Pharmacology CE
  • 0.25 Contact hours
$0.00
0.25 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and for non- members. This session will review evidence-based practice for the diagnosis and treatment of skin and soft tissue infections in children. Review the key clinical diagnostic features for skin and soft tissue infections. Apply this knowledge to clinical case scenarios.
  • FREE for Members
  • Infectious Disease
  • Pharmacology CE
  • 0.50 Contact hours
$0.00
0.5 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and for non- members. This session will review evidence-based practice for the diagnosis and treatment of C.diff in children in ambulatory care. Apply this knowledge to clinical case scenarios.
  • FREE for Members
  • Infectious Disease
  • Pharmacology CE
  • 0.50 Contact hours
$0.00
0.5 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and for non- members. This session will review evidence-based practice for the diagnosis and treatment of community acquired pneumonia in children in the ambulatory care environment. Apply this knowledge to clinical case scenarios.
  • FREE for Members
  • Infectious Disease
  • Pharmacology CE
  • 0.50 Contact hours
$0.00
0.5 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and for non- members. This session will review evidence-based practice for the diagnosis and treatment of acute otitis media in children in ambulatory care. Learn about the value of delayed prescribing of antibiotics. Apply this knowledge to clinical case scenarios.
  • FREE for Members
  • Infectious Disease
  • Pharmacology CE
  • 0.50 Contact hours
$0.00
0.5 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and for non- members. This session will review the epidemiology and etiology of common tick-borne illnesses across the United States. The common presentations of various tick-borne infections are included. Clinical case scenarios are utilized to demonstrate appropriate diagnosis and treatment of tick-borne illnesses.
  • FREE for Members
  • Infectious Disease
  • Pharmacology CE
  • 0.50 Contact hours
$0.00
0.5 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and for non- members. This session will review evidence-based practice for the diagnosis and treatment of Group A Streptococcus. Learn about the importance of utilizing the Modified Centor Score to determine when to test for Group A Strep. Review evidence for appropriate antibiotic treatment for Group A Strep. Apply this new knowledge to clinical case scenarios.
  • Acute Care
  • FREE for Members
  • Infectious Disease
  • Pharmacology CE
  • 1.00 Contact hours
$0.00
1.0 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and for non- members. Lyme disease is the most common vector-borne disease in the United States, with approximately 476,000 people diagnosed and treated each year. Many patients with undiagnosed and untreated early Lyme disease will progress to disseminated Lyme disease. Disseminated Lyme disease is often treated in the acute care setting and may be difficult for providers to identify without the classic erythema migrans rash of early localized Lyme disease. This webinar will review presentations of disseminated Lyme disease in pediatric patients as well as appropriate diagnostics and treatment plans utilizing the 2020 Lyme disease guidelines.
  • FREE for Members
  • Pharmacology CE
  • 1.00 Contact hours
$10.00
1.0 NAPNAP contact hour of which 0.50 contain pharmacology content (Rx). This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. This study aimed to describe pneumococcal polysaccharide vaccine-23 (PPSV23) vaccination use in high-risk pediatric patients with chronic heart disease (CHD). J Pediatr Health Care. (2023) 37, 710-717.